S&P 500   4,353.87 (+0.09%)
DOW   34,302.60 (+0.39%)
QQQ   344.93 (+0.10%)
AAPL   161.12 (+0.90%)
MSFT   302.08 (+1.81%)
FB   298.70 (+1.38%)
GOOGL   2,612.68 (+1.08%)
AMZN   2,836.05 (+2.11%)
TSLA   859.85 (-8.27%)
NVDA   220.81 (-3.03%)
BABA   112.66 (-0.63%)
NIO   21.55 (-4.90%)
AMD   104.16 (-5.92%)
CGC   6.96 (-3.73%)
MU   80.19 (-2.17%)
GE   89.20 (-0.13%)
T   24.26 (+0.04%)
F   19.84 (-0.35%)
DIS   136.12 (+1.89%)
AMC   14.86 (-6.78%)
PFE   54.21 (+2.26%)
ACB   3.88 (-4.43%)
BA   192.44 (-0.94%)
S&P 500   4,353.87 (+0.09%)
DOW   34,302.60 (+0.39%)
QQQ   344.93 (+0.10%)
AAPL   161.12 (+0.90%)
MSFT   302.08 (+1.81%)
FB   298.70 (+1.38%)
GOOGL   2,612.68 (+1.08%)
AMZN   2,836.05 (+2.11%)
TSLA   859.85 (-8.27%)
NVDA   220.81 (-3.03%)
BABA   112.66 (-0.63%)
NIO   21.55 (-4.90%)
AMD   104.16 (-5.92%)
CGC   6.96 (-3.73%)
MU   80.19 (-2.17%)
GE   89.20 (-0.13%)
T   24.26 (+0.04%)
F   19.84 (-0.35%)
DIS   136.12 (+1.89%)
AMC   14.86 (-6.78%)
PFE   54.21 (+2.26%)
ACB   3.88 (-4.43%)
BA   192.44 (-0.94%)
S&P 500   4,353.87 (+0.09%)
DOW   34,302.60 (+0.39%)
QQQ   344.93 (+0.10%)
AAPL   161.12 (+0.90%)
MSFT   302.08 (+1.81%)
FB   298.70 (+1.38%)
GOOGL   2,612.68 (+1.08%)
AMZN   2,836.05 (+2.11%)
TSLA   859.85 (-8.27%)
NVDA   220.81 (-3.03%)
BABA   112.66 (-0.63%)
NIO   21.55 (-4.90%)
AMD   104.16 (-5.92%)
CGC   6.96 (-3.73%)
MU   80.19 (-2.17%)
GE   89.20 (-0.13%)
T   24.26 (+0.04%)
F   19.84 (-0.35%)
DIS   136.12 (+1.89%)
AMC   14.86 (-6.78%)
PFE   54.21 (+2.26%)
ACB   3.88 (-4.43%)
BA   192.44 (-0.94%)
S&P 500   4,353.87 (+0.09%)
DOW   34,302.60 (+0.39%)
QQQ   344.93 (+0.10%)
AAPL   161.12 (+0.90%)
MSFT   302.08 (+1.81%)
FB   298.70 (+1.38%)
GOOGL   2,612.68 (+1.08%)
AMZN   2,836.05 (+2.11%)
TSLA   859.85 (-8.27%)
NVDA   220.81 (-3.03%)
BABA   112.66 (-0.63%)
NIO   21.55 (-4.90%)
AMD   104.16 (-5.92%)
CGC   6.96 (-3.73%)
MU   80.19 (-2.17%)
GE   89.20 (-0.13%)
T   24.26 (+0.04%)
F   19.84 (-0.35%)
DIS   136.12 (+1.89%)
AMC   14.86 (-6.78%)
PFE   54.21 (+2.26%)
ACB   3.88 (-4.43%)
BA   192.44 (-0.94%)
NASDAQ:HARP

Harpoon Therapeutics Stock Forecast, Price & News

$5.04
-0.39 (-7.18%)
(As of 01/27/2022 12:14 PM ET)
Add
Compare
Today's Range
$5.04
$5.50
50-Day Range
$5.09
$8.08
52-Week Range
$4.85
$24.20
Volume
1,080 shs
Average Volume
214,311 shs
Market Capitalization
$165.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.8
30 days | 90 days | 365 days | Advanced Chart
Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Harpoon Therapeutics logo

About Harpoon Therapeutics

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
78
Year Founded
N/A

Sales & Book Value

Annual Sales
$17.44 million
Book Value
$2.12 per share

Profitability

Net Income
$-49.91 million
Net Margins
-397.64%
Pretax Margin
-397.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
31,308,000
Market Cap
$165.05 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/27/2022
Next Earnings (Estimated)
3/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

733rd out of 1,419 stocks

Biological Products, Except Diagnostic Industry

116th out of 207 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

Is Harpoon Therapeutics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics
or view top-rated stocks.

How has Harpoon Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HARP stock has decreased by 61.4% and is now trading at $5.04.
View which stocks have been most impacted by COVID-19
.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Harpoon Therapeutics
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.01. The business earned $4.48 million during the quarter, compared to the consensus estimate of $6.38 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 69.97% and a negative net margin of 397.64%.
View Harpoon Therapeutics' earnings history
.

What price target have analysts set for HARP?

7 brokerages have issued twelve-month price targets for Harpoon Therapeutics' stock. Their forecasts range from $14.00 to $40.00. On average, they expect Harpoon Therapeutics' share price to reach $28.17 in the next year. This suggests a possible upside of 458.9% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Julia Marie Eastland, President, Chief Executive Officer & Director
  • Georgia L. Erbez, Chief Financial Officer (LinkedIn Profile)
  • Rick Austin, Vice President-Research
  • Natalie R. Sacks, Chief Medical Officer
  • Holger Wesche, Chief Scientific Officer

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cutler Group LP (0.00%). Company insiders that own Harpoon Therapeutics stock include Ansbert Gadicke, Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Natalie Sacks.
View institutional ownership trends for Harpoon Therapeutics
.

Which institutional investors are buying Harpoon Therapeutics stock?

HARP stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Harpoon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $5.04.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics has a market capitalization of $165.05 million and generates $17.44 million in revenue each year. The company earns $-49.91 million in net income (profit) each year or ($3.43) on an earnings per share basis.

How many employees does Harpoon Therapeutics have?

Harpoon Therapeutics employs 78 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

Where are Harpoon Therapeutics' headquarters?

Harpoon Therapeutics is headquartered at 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-7400 or via email at [email protected].


This page was last updated on 1/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.